Brookfield, KF, Cheung, MC, Koniaris, LG, Sola, JE, Fischer, AC. A population-based analysis of 1037 malignant ovarian tumors in the pediatric population. J Surg Res 2009. doi:10.1016/j.jss.2009.03.069.Google Scholar

Schultz, KAP, Harris, AK, Finch, M, et al. DICER1-related Sertoli–Leydig cell tumor and gynandroblastoma: clinical and genetic findings from the International Ovarian and Testicular Stromal Tumor Registry. Gynecol Oncol 2017. doi:10.1016/j.ygyno.2017.09.034.CrossRefGoogle Scholar

Schultz, KAP, Harris, A, Messinger, Y, et al. Ovarian tumors related to intronic mutations in DICER1: a report from the international ovarian and testicular stromal tumor registry. Fam Cancer 2016. doi:10.1007/s10689-015-9831-y.CrossRefGoogle Scholar

Lang, JD, Hendricks, WPD. Identification of driver mutations in rare cancers: the role of SMARCA4 in small cell carcinoma of the ovary, hypercalcemic type (SCCOHT). Methods Mol Biol 2018. doi:10.1007/978-1-4939-7471-9_20.CrossRefGoogle Scholar

Marro, A, Allen, LM, Kives, SL, Moineddin, R, Chavhan, GB. Simulated impact of pelvic MRI in treatment planning for pediatric adnexal masses. Pediatr Radiol 2016. doi:10.1007/s00247-016-3606-y.Google Scholar

Epelman, M, Chikwava, KR, Chauvin, N, Servaes, S. Imaging of pediatric ovarian neoplasms. Pediatr Radiol 2011. doi:10.1007/s00247-011-2128-x.CrossRefGoogle Scholar

Capito, C, Arnaud, A, Hameury, F, et al. Dysgerminoma and gonadal dysgenesis: the need for a new diagnosis tree for suspected ovarian tumours. J Pediatr Urol 2011. doi:10.1016/j.jpurol.2011.02.021.Google Scholar

Renaud, EJ, Sømme, S, Islam, S, et al. Ovarian masses in the child and adolescent: an American Pediatric Surgical Association Outcomes and Evidence-Based Practice Committee systematic review. J Pediatr Surg 2019. doi:10.1016/j.jpedsurg.2018.08.058.CrossRefGoogle Scholar

Tamauchi, S, Kajiyama, H, Yoshihara, M, et al. Reproductive outcomes of 105 malignant ovarian germ cell tumor survivors: a multicenter study. Am J Obstet Gynecol 2018. doi:10.1016/j.ajog.2018.07.021.Google Scholar

Rogers, PC, Olson, TA, Cullen, JW, et al. Treatment of children and adolescents with stage II testicular and stages I and II ovarian malignant germ cell tumors: a Pediatric Intergroup study – Pediatric Oncology Group 9048 and Children’s Cancer Group 8891. J Clin Oncol 2004;22:3563–3569.CrossRefGoogle ScholarPubMed

Madenci, AL, Vandewalle, RJ, Dieffenbach, BV, et al. Multicenter pre-operative assessment of pediatric ovarian malignancy. J Pediatr Surg 2019. doi:10.1016/j.jpedsurg.2019.02.019.CrossRefGoogle Scholar

Madenci, AL, Levine, BS, Laufer, MR, et al. Preoperative risk stratification of children with ovarian tumors. J Pediatr Surg 2016. doi:10.1016/j.jpedsurg.2016.05.004.CrossRefGoogle Scholar

Abbas, PI, Dietrich, JE, Francis, JA, et al. Ovarian-sparing surgery in pediatric benign ovarian tumors. J Pediatr Adolesc Gynecol 2016. doi:10.1016/j.jpag.2016.03.009.CrossRefGoogle Scholar

Faure-Conter, C, Pashankar, F. Immature ovarian teratoma: when to give adjuvant therapy? J Pediatr Hematol Oncol 2017. doi:10.1097/MPH.0000000000000950.CrossRefGoogle Scholar

Pashankar, F, Hale, JP, Dang, H, et al. Is adjuvant chemotherapy indicated in ovarian immature teratomas? A combined data analysis from the Malignant Germ Cell Tumor International Collaborative. Cancer 2016. doi:10.1002/cncr.29732.CrossRefGoogle Scholar

Terenziani, M, Cecchetto, G, Inserra, A, et al. Mature and immature teratoma: results of the second pediatric AIEOP (Associazione Italiana Di Ematologia Oncologia Pediatrica) Italian study. Pediatr Blood Cancer 2014;61:S120. doi:10.1002/pbc.25314.Google Scholar

Satoh, T, Aoki, Y, Kasamatsu, T, et al. Administration of standard-dose BEP regimen (bleomycin + etoposide + cisplatin) is essential for treatment of ovarian yolk sac tumour. Eur J Cancer 2015. doi:10.1016/j.ejca.2014.12.004.CrossRefGoogle Scholar

Shaikh, F, Cullen, JW, Olson, TA, et al. Reduced and compressed cisplatin-based chemotherapy in children and adolescents with intermediate-risk extracranial malignant germ cell tumors: a report from the Children’s Oncology Group. J Clin Oncol 2017. doi:10.1200/JCO.2016.67.6544.CrossRefGoogle Scholar

Frazier, AL, Stoneham, S, Rodriguez-Galindo, C, et al. Comparison of carboplatin versus cisplatin in the treatment of paediatric extracranial malignant germ cell tumours: a report of the Malignant Germ Cell International Consortium. Eur J Cancer 2018;98:30–37.CrossRefGoogle ScholarPubMed

Shah, R, Xia, C, Krailo, M, et al. Is carboplatin-based chemotherapy as effective as cisplatin-based chemotherapy in the treatment of advanced-stage dysgerminoma in children, adolescents and young adults? Gynecol Oncol 2018. doi:10.1016/j.ygyno.2018.05.025.Google Scholar

Frazier, AL, Hale, JP, Rodriguez-Galindo, C, et al. Revised risk classification for pediatric extracranial germ cell tumors based on 25 years of clinical trial data from the United Kingdom and United States. J Clin Oncol 2015. doi:10.1200/JCO.2014.58.3369.Google Scholar

Fresneau, B, Orbach, D, Faure-Conter, C, et al. Sex-cord stromal tumors in children and teenagers: results of the TGM-95 Study. Pediatr Blood Cancer 2015. doi:10.1002/pbc.25614.CrossRefGoogle Scholar

Schneider, DT, Calaminus, G, Wessalowksi, R, et al. Ovarian sex cord–stromal tumors in children and adolescents. J Clin Oncol 2003;21:2357–2363. doi:10.1200/JCO.2003.05.038.Google Scholar

Schneider, DT, Orbach, D, Cecchetto, G, et al. Ovarian Sertoli Leydig cell tumours in children and adolescents: an analysis of the European Cooperative Study Group on Pediatric Rare Tumors (EXPeRT). Eur J Cancer 2015;51:543–550.CrossRefGoogle Scholar

Cecchetto, G, Ferrari, A, Bernini, G, et al. Sex cord stromal tumors of the ovary in children: a clinicopathological report from the Italian TREP project. Pediatr Blood Cancer 2011. doi:10.1002/pbc.22918.Google Scholar

Calaminus, G, Wessalowski, R, Harms, D, Göbel, U. Juvenile granulosa cell tumors of the ovary in children and adolescents: results from 33 patients registered in a prospective cooperative study. Gynecol Oncol 1997. doi:10.1006/gyno.1997.4695.Google Scholar

Powell, JL, Kotwall, CA, Shiro, BC. Fertility-sparing surgery for advanced juvenile granulosa cell tumor of the ovary. J Pediatr Adolesc Gynecol 2014. doi:10.1016/j.jpag.2013.10.001.Google Scholar

Distelmaier, F, Calaminus, G, Harms, D, et al. Ovarian small cell carcinoma of the hypercalcemic type in children and adolescents: a prognostically unfavorable but curable disease. Cancer 2006;107:2298–2306.CrossRefGoogle ScholarPubMed

Pressey, JG, Kelly, DR, Hawthorne, HT. Successful treatment of preadolescents with small cell carcinoma of the ovary hypercalcemic type. J Pediatr Hematol Oncol 2013. doi:10.1097/MPH.0b013e318282cca8.Google Scholar

Ripperger, T, Bielack, SS, Borkhardt, A, et al. Childhood cancer predisposition syndromes: a concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatric Oncology and Hematology. Am J Med Genet Part A 2017. doi:10.1002/ajmg.a.38142.Google Scholar

Kurobe, M, Kawai, K, Oikawa, T, et al. Paclitaxel, ifosfamide, and cisplatin (TIP) as salvage and consolidation chemotherapy for advanced germ cell tumor. J Cancer Res Clin Oncol 2015. doi:10.1007/s00432-014-1760-x.Google Scholar

Einhorn, LH. Salvage chemotherapy for patients with germ cell tumors: is there a best regimen? J Clin Oncol 2012. doi:10.1200/jco.2011.40.4160.Google Scholar

Rashdan, S, Einhorn, LH. Salvage therapy for patients with germ cell tumor. J Oncol Pract 2016. doi:10.1200/jop.2016.011411.CrossRefGoogle Scholar

Faure-Conter, C, Orbach, D, Cropet, C, et al. Salvage therapy for refractory or recurrent pediatric germ cell tumors: the French SFCE experience. Pediatr Blood Cancer 2014. doi:10.1002/pbc.24730.CrossRefGoogle Scholar

Pashankar, F, Frazier, AL, Krailo, M, et al. Treatment of refractory germ cell tumors in children with paclitaxel, ifosfamide, and carboplatin: a report from the Children’s Oncology Group AGCT0521 study. Pediatr Blood Cancer 2018;65.Google Scholar

Motzer, RJ, Mazumdar, M, Sheinfeld, J, et al. Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients. J Clin Oncol 2000. doi:10.1200/JCO.2000.18.6.1173.Google Scholar

Fenner, MH, Beutel, G, Grünwald, V. Targeted therapies for patients with germ cell tumors. Expert Opin Investig Drugs 2008. doi:10.1517/13543784.17.4.511.Google Scholar

Wessalowski, R, Schneider, DT, Mils, O, et al. Regional deep hyperthermia for salvage treatment of children and adolescents with refractory or recurrent non-testicular malignant germ-cell tumours: an open-label, non-randomised, single-institution, phase 2 study. Lancet Oncol 2013. doi:10.1016/S1470-2045(13)70271-7.Google Scholar

Hayes-Jordan, A, Lopez, C, Green, HL, et al. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in pediatric ovarian tumors: a novel treatment approach. Pediatr Surg Int 2016. doi:10.1007/s00383-015–3814-9.CrossRefGoogle Scholar

Dicken, BJ, Billmire, DF, Krailo, M, et al. Gonadal dysgenesis is associated with worse outcomes in patients with ovarian nondysgerminomatous tumors: a report of the Children’s Oncology Group AGCT 0132 study. Pediatr Blood Cancer 2018. doi:10.1002/pbc.26913.CrossRefGoogle Scholar

Royal College of Obstetric s and Gynaecology and British Society for Gynaecological Endoscopy. Management of suspected ovarian masses in premenopausal women. Green-top Guideline No. 62. 2011.Google Scholar

Royal College of Obstetrics and Gynaecology. The management of ovarian cysts in postmenopausal women. Green-top Guideline No. 34. 2016.Google Scholar

American College of Obstetricians and Gynaecologists. Evaluation and management of adnexal masses. Practice Bulletin. 2016Google Scholar

National Institute for Health and Care Excellence. Ovarian cancer: recognition and initial management. Clinical Guideline No. 122. 2011Google Scholar

Schmeler, KM, Mayo-Smith, WW, Peipert, JF, et al. Adnexal masses in pregnancy: surgery compared with observation. Obstet Gynecol 2005;105:1098–1103.Google Scholar

Modesitt, SC, Pavlik, EJ, Ueland, FR, et al. Risk of malignancy in unilocular ovarian cystic tumours less than 10 centimetres in diameter. Obstet Gynecol 2003;102:594–599.Google ScholarPubMed

Fischerova, D, Zikan, M, Dundr, P, Cibula, D. Diagnosis, treatment, and follow-up of borderline ovarian tumors. Oncologist 2012;17:1515–1533.CrossRefGoogle ScholarPubMed

Fotopoulou, C, British Gynaecological Cancer Society (BGCS). Epithelial ovarian/fallopian tube/primary peritoneal cancer guidelines: recommendations for practice. 2017.CrossRefGoogle Scholar

Khunamornpong, S, Settakorn, J, Sukpan, K, Suprasert, P, Siriaunkgul, S. Mucinous tumor of low malignant potential (‘borderline’ or ‘atypical proliferative’ tumor) of the ovary: a study of 171 cases with the assessment of intraepithelial carcinoma and microinvasion. Int J Gynecol Pathol 2011;30:218–213.CrossRefGoogle ScholarPubMed

Faluyi, O, Mackean, M, Gourley, C, Bryant, A, Dickinson, HO. Interventions for the treatment of borderline ovarian tumours. Cochrane Database Syst Rev 2010;8:CD007696.Google Scholar

Leiserowitz, GS. Managing ovarian masses during pregnancy. Obstet Gynecol Surv 2006;61:463–470.Google Scholar

Ronnett, BM, Kajdacsy-Balla, A, Gilks, CB, et al. Mucinous borderline ovarian tumors: points of general agreement and persistent controversies regarding nomenclature, diagnostic criteria, and behavior. Hum Pathol 2004;35:949–960.Google Scholar

Ray-Coquard, I, Morice, P, Lorusso, D, et al. Non-epithelial ovarian cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018;29(Suppl. 4):iv1–iv18.Google Scholar

Young, RH. Sex cord-stromal, steroid cell, and other ovarian tumors with endocrine, paraendocrine, and paraneoplastic manifestations. In: Blaustein’s Pathology of the Female Genital Tract, 6th edition. New York: Springer, 2011.Google Scholar

Talerman, A, Vang, R. Germ cell tumors of the ovary. In: Blaustein’s Pathology of the Female Genital Tract, 6th edition. New York: Springer, 2011.Google Scholar

Brown, J, Friedlander, M, Backes, FJ, et al. Gynecologic Cancer Intergroup (GCIG) consensus review for ovarian germ cell tumors. Int J Gynecol Cancer 2014;24(9 Suppl 3):S48–S54.Google Scholar

Seckl, M, Rustin, G. Malignant ovarian germ cell tumours. In: Textbook of Gyneacological Oncology. Ankara: Gunes Publishing, 2016.Google Scholar

Ray-Coquard, I, Brown, J, Harter, P, et al. Gynecologic Cancer Intergroup (GCIG) consensus review for ovarian sex cord stromal tumors. Int J Gynecol Cancer 2014;24:S42–S47CrossRefGoogle ScholarPubMed

Peiretti, M, Angioni, S, Corda, V, Colombo, N. Sex cord-stromal tumors of the ovary. In: Textbook of Gyneacological Oncology. Ankara: Gunes Publishing, 2016.Google Scholar

Berek, JS, Kehoe, ST, Kumar, L, Friedlander, M. Cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet 2018;143(Suppl. 2):59–78.Google Scholar

Disaia, PJ, Creasman, WT, Mannel, RS, Mcmeekin, DS, Mutch, DG. Germ cell, stromal, and other ovarian tumors. In: Clinical Gynecologic Oncology, 9th edition. Philadelphia, PA: Elsevier, 2018.Google Scholar

Bryant, CS, Kumar, A, Shah, JP, et al. Racial disparities in survival among patients with germ cell tumors of the ovary: United States. Gynecologic Oncol 2009;114:437–441.Google Scholar

Kurman, RJ, Carcangiu, ML, Herrington, CS, Young, RH. Tumors of the ovary. In: WHO Classification of Tumors of Female Reproductive Organs, 4th edition. Lyon: IARC, 2014.Google Scholar

Gershenson, DM. Current advances in the management of malignant germ cell and sex cord-stromal tumors of the ovary. Gynecol Oncol 2012;125:515–517.CrossRefGoogle ScholarPubMed

Gershenson, DM, Goff, B, Pappo, AS, Garcia, RL. Ovarian germ cell tumors: pathology, clinical manifestations, and diagnosis. UpToDate. 2017. Available at: www.uptodate.com/contents/ovarian-germ-cell-tumors-pathology-clinical-manifestations-and-diagnosis.Google Scholar

Berek, N. Germ cell and nonepithelial ovarian cancer. In: Berek & Hacker’s Gynecologic Oncology. Philadelphia, PA: Wolters Kluwer, 2015.Google Scholar

Lee-Jones, L. Ovary: germ cell tumors, solid tumor section. Atlas Genet Cytogenet Oncol Haematol 2003;7(4).Google Scholar

Melamed, A, Keating, NL, Clemmer, JT, et al. Laparoscopic staging for apparent stage I epithelial ovarian cancer. Am J Obstet Gynecol 2017;216:50.e1–50.e12.CrossRefGoogle ScholarPubMed

Nasioudis, D, Minis, E, Chapman-Davis, E, et al. Minimally invasive surgery staging of apparent stage I malignant ovarian germ cell tumors; prevalence and outcomes. J Min Invasive Gynecol 2019;26:471–476.Google Scholar

Gremeau, AS, Bourdel, N, Jardon, K, et al. Surgical management of non-epithelial ovarian malignancies: advantages and limitations of laparoscopy. Eur J Obstet Gynecol Reprod Biol 2014;172:106–110.Google Scholar

Talukdar, S, Kumar, S, Bhatla, N, et al. Neo-adjuvant chemotherapy in the treatment of advanced malignant germ cell tumors of ovary. Gynecol Oncol 2014;132:28–32.CrossRefGoogle ScholarPubMed

Di Tucci, C, Casorelli, A, Morrocchi, E, et al. Fertility management for malignant ovarian germ cell tumors patients. Crit Rev Oncol Hematol 2017;120:34–42.CrossRefGoogle ScholarPubMed

Feichtinger, M, Rodriguez-Wallberg, KA. Fertility preservation in women with cervical, endometrial or ovarian cancers. Gynecologic Oncol Res Prac 2016;3:8.CrossRefGoogle ScholarPubMed

National Comprehensive Cancer Network (NCCN). Guidelines: ovarian cancer, including fallopian tube cancer and primary peritoneal cancer. Version 4. 2017.Google Scholar

Murugaese, N, Schmid, P, Dancey, G, et al. Malignant ovarian germ cell tumors: identification of novel prognostic markers and long-term outcomes after multimodality treatment. J Clin Oncol 2006;24:4862–4866.CrossRefGoogle Scholar

Horta, M, Cunha, TM. Sex cord-stromal tumors of the ovary: a comprehensive review and update for radiologists. Diagn Interv Radiol 2015;21:277–286.Google Scholar

Nasioudis, D, Kanninen, TT, Holcomb, K, Sisti, G, Witkin, SS. Prevalence of lymph node metastasis and prognostic significance of lymphadenectomy in apparent early-stage malignant ovarian sex cord-stromal tumors. Gynecol Oncol 2017;145:243–247.Google Scholar

Bergamini, A, Ferrandina, G, Candiani, M, et al. Laparoscopic surgery in the treatment of stage I adult granulosa cells tumors of the ovary: results from the MITO-9 study. Eur J Surg Oncol 2018;44:766–770.CrossRefGoogle Scholar

Kurman, RJ, Shih, IeM. Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol 2008;27:151–160.Google ScholarPubMed

Levanon, K, Crum, C, Drapkin, R. New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J Clin Oncol 2008;26:5284–5293.Google Scholar

Kurman, RJ, Shih, IeM. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 2010;34:433–443.CrossRefGoogle ScholarPubMed

Anglesio, MS, Papadopoulos, N, Ayhan, A, et al. Cancer-associated mutations in endometriosis without cancer. N Engl J Med 2017;376:1835–1848.CrossRefGoogle ScholarPubMed

Kvaskoff, M, Horne, AW, Missmer, SA. Informing women with endometriosis about ovarian cancer risk. Lancet 2017;390:2433–2434.CrossRefGoogle ScholarPubMed

Bolton, KL, Chenevix-Trench, G, Goh, C, et al. Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA 2012;307:382–390.Google Scholar

Norquist, BM, Harrell, MI, Brady, MF, et al. Inherited mutations in women with ovarian carcinoma. JAMA Oncol 2016;2:482–490.Google Scholar

Finch, AP, Lubinski, J, Moller, P, et al. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol 2014;32:1547–1553.CrossRefGoogle ScholarPubMed

Buys, SS, Partridge, E, Black, A, et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA 2011;305:2295–2303.CrossRefGoogle ScholarPubMed

Jacobs, IJ, Menon, U, Ryan, A, et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet 2016;387:945–956.Google Scholar

Kobayashi, H, Yamada, Y, Sado, T, et al. A randomized study of screening for ovarian cancer: a multicenter study in Japan. Int J Gynecol Cancer 2008;18:414–420.CrossRefGoogle ScholarPubMed

van Nagell, JR, Jr., Miller, RW, DeSimone, CP, et al. Long-term survival of women with epithelial ovarian cancer detected by ultrasonographic screening. Obstet Gynecol 2011;118:1212–1221.Google Scholar

van der Velde, NM, Mourits, MJ, Arts, HJ, et al. Time to stop ovarian cancer screening in BRCA1/2 mutation carriers? Int J Cancer 2009;124:919–923.Google Scholar

Goff, BA, Mandel, LS, Melancon, CH, Muntz, HG. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA 2004;291:2705–2712.CrossRefGoogle ScholarPubMed

Schnatz, PF, Guile, M, O’Sullivan, DM, Sorosky, JI. Clinical significance of atypical glandular cells on cervical cytology. Obstet Gynecol 2006;107:701–708.Google Scholar

Jacob, F, Meier, M, Caduff, R, et al. No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting. Gynecol Oncol 2011;121:487–491.CrossRefGoogle ScholarPubMed

Zaino, R, Whitney, C, Brady, MF, et al. Simultaneously detected endometrial and ovarian carcinomas: a prospective clinicopathologic study of 74 cases: a gynecologic oncology group study. Gynecol Oncol 2001;83:355–362.Google Scholar

Jacobs, I, Oram, D, Fairbanks, J, et al. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol 1990;97:922–929.Google Scholar

Chia, YN, Marsden, DE, Robertson, G, Hacker, NF. Triage of ovarian masses. Aust N Z J Obstet Gynaecol 2008;48:322–328.Google Scholar

Manegold-Brauer, G, Buechel, J, Knipprath-Meszaros, A, et al. Improved detection rate of ovarian cancer using a 2-step triage model of the risk of malignancy index and expert sonography in an outpatient screening setting. Int J Gynecol Cancer 2016;26:1062–1069.Google Scholar

Timmerman, D, Van Calster, B, Testa, A, et al. Predicting the risk of malignancy in adnexal masses based on the Simple Rules from the International Ovarian Tumor Analysis group. Am J Obstet Gynecol 2016;214:424–437.Google Scholar

Dann, RB, DeLoia, JA, Timms, KM, et al. BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer. Gynecol Oncol 2012;125:677–682.CrossRefGoogle ScholarPubMed

Pennington, KP, Walsh, T, Harrell, MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res 2014;20:764–775.CrossRefGoogle ScholarPubMed

Colombo, N, Sessa, C, du Bois, A, et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent diseasedagger. Ann Oncol 2019;30:672–705.Google Scholar

Wilson, MK, Pujade-Lauraine, E, Aoki, D, et al. Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease. Ann Oncol 2017;28:727–732.Google Scholar

Alsop, K, Fereday, S, Meldrum, C, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol 2012;30:2654–2663.CrossRefGoogle ScholarPubMed

Vergote, I, De Brabanter, J, Fyles, A, et al. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet 2001;357:176–182.CrossRefGoogle ScholarPubMed

Timmers, PJ, Zwinderman, AH, Coens, C, Vergote, I, Trimbos, JB. Understanding the problem of inadequately staging early ovarian cancer. Eur J Cancer 2010;46:880–884.Google Scholar

Harter, P, Sehouli, J, Lorusso, D, et al. LION: Lymphadenectomy in Ovarian Neoplasms – a prospective randomized AGO study group led gynecologic cancer intergroup trial. J Clin Oncol 2017;35(Suppl. 15):5500.Google Scholar

Bristow, RE, Tomacruz, RS, Armstrong, DK, Trimble, EL, Montz, FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002;20:1248–1259.Google Scholar

du Bois, A, Reuss, A, Pujade-Lauraine, E, et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO). Cancer 2009;115:1234–1244.CrossRefGoogle Scholar

Harter, P, du Bois, A, Hahmann, M, et al. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol 2006;13:1702–1710.Google Scholar

Bois, AD, Vergote, I, Ferron, G, et al. Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III/ENGOT ov20. J Clin Oncol 2017;35(Suppl. 15):5501.CrossRefGoogle Scholar

Du Bois A, Sehouli J, Vergote I, et al. Randomized phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer: Final analysis of AGO DESKTOP III/ENGOT-ov20. J Clin Oncol. DOI: 10.1200/JCO.2020.38.15_suppl.6000Google Scholar

Vergote, I, Trope, CG, Amant, F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010;363:943–953.CrossRefGoogle ScholarPubMed

Kehoe, S, Hook, J, Nankivell, M, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet 2015;386:249–257.CrossRefGoogle ScholarPubMed

Parmar, MK, Ledermann, JA, Colombo, N, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003;361:2099–2106.Google Scholar

Pignata, S, Scambia, G, Ferrandina, G, et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial. J Clin Oncol 2011;29:3628–3635.Google Scholar

Collinson, F, Qian, W, Fossati, R, et al. Optimal treatment of early-stage ovarian cancer. Ann Oncol 2014;25:1165–1171.Google Scholar

Wagner, U, Marth, C, Largillier, R, et al. Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. Br J Cancer 2012;107:588–591.CrossRefGoogle ScholarPubMed

Aghajanian, C, Blank, SV, Goff, BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012;30:2039–2045.Google Scholar

Fisterer, J. Carboplatin/pegylated liposomal doxorubicin/bevacizumab (CD-BEV) vs. carboplatin/gemcitabine/bevacizumab (CG-BEV) in patients with recurrent ovarian cancer: a prospective randomized phase III ENGOT/GCIG-Intergroup study (AGO study group, AGO-Austria, ANZGOG, GINECO, SGCTG) (9330). Ann Oncol 2018;29(Suppl. 8):viii332–viii358.Google Scholar

Poveda, A, Vergote, I, Tjulandin, S, et al. Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6–12 months) subpopulation of OVA-301 phase III randomized trial. Ann Oncol 2011;22:39–48.CrossRefGoogle ScholarPubMed

Katsumata, N, Yasuda, M, Takahashi, F, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 2009;374:1331–1338.Google Scholar

Clamp, AR. ICON8: a GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/fallopian tube/primary peritoneal carcinoma (EOC) treatment – results of primary progression-free survival (PFS) analysis. Ann Oncol 2017;28(Suppl. 5). doi:10.1093/annonc/mdx440.Google Scholar

Chan, JK, Brady, MF, Penson, RT, et al. Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer. N Engl J Med 2016;374:738–748.Google Scholar

Pignata, S, Scambia, G, Katsaros, D, et al. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 2014;15:396–405.Google Scholar

Pujade-Lauraine, E, Hilpert, F, Weber, B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol 2014;32:1302–1308.Google Scholar

Jaaback, K, Johnson, N, Lawrie, TA. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev 2016;1:CD005340.Google Scholar

van Driel, WJ, Koole, SN, Sikorska, K, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med 2018;378:230–240.CrossRefGoogle ScholarPubMed

Perren, TJ, Swart, AM, Pfisterer, J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011;365:2484–2496.Google Scholar

Burger, RA, Brady, MF, Bookman, MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011;365:2473–2483.Google Scholar

Pignata, S. Chemotherapy plus or minus bevacizumab for platinum-sensitive ovarian cancer patients recurring after a bevacizumab containing first line treatment: the randomized phase 3 trial MITO16B-MaNGO OV2B-ENGOT OV17. J Clin Oncol 2018;36(Suppl.):5506.Google Scholar

Franzese, E, Centonze, S, Diana, A, et al. PARP inhibitors in ovarian cancer. Cancer Treat Rev 2019;73:1–9.Google Scholar

Moore, K, Colombo, N, Scambia, G, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 2018;379:2495–2505.Google Scholar

Mirza, MR, Monk, BJ, Herrstedt, J, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med 2016;375:2154–2164.Google Scholar

Fruscio, R, de Haan, J, Van Calsteren, K, et al. Ovarian cancer in pregnancy. Best Pract Res Clin Obstet Gynaecol 2017;41:108–117.Google Scholar

Rustin, GJ, van der Burg, ME, Griffin, CL, et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet 2010;376:1155–1163.Google Scholar

Hughes, LE. Classification of benign breast disorders: the ANDI classification based on physiological processes within the normal breast. Br Med Bull 1991;47:251–257.Google Scholar

Dupont, WD, Page, DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 1985;312:146–151.Google Scholar

Neal, L, Sandhu, NP, Hieken, TJ, et al. Diagnosis and management of benign, atypical, and indeterminate breast lesions detected on core needle biopsy. Mayo Clin Proc 2014;89:536–547.CrossRefGoogle ScholarPubMed

Hartmann, LC, Sellers, TA, Frost, MH, et al. Benign breast disease and the risk of breast cancer. N Engl J Med 2005;353:229–237.Google Scholar

Orr, B, Kelley, JL. Benign breast diseases: evaluation and management. Clin Obstet Gynecol 2016;59:710–726.Google Scholar

Rungruang, B, Kelley, JL. Benign breast diseases: epidemiology, evaluation, and management. Clin Obstet Gynecol 2011;54:110–124.CrossRefGoogle ScholarPubMed

Rohan, TE, Miller, AB. Hormone replacement therapy and risk of benign proliferative epithelial disorders of the breast. Eur J Cancer Prev 1999;8:123–130.Google Scholar

Tan-Chiu, E, Wang, J, Costantino, JP, et al. Effects of tamoxifen on benign breast disease in women at high risk for breast cancer. J Natl Cancer Inst 2003;95:302–307.Google Scholar

Cho, SH, Park, SH. Mimickers of breast malignancy on breast sonography. J Ultrasound Med 2013;32:2029–2036.Google Scholar

Liu, L, Zhou, F, Wang, P, et al. Periductal mastitis: an inflammatory disease related to bacterial infection and consequent immune responses? Mediators Inflamm 2017;2017:5309081.Google Scholar

Koerner, FC. Epithelial proliferations of ductal type. Semin Diagn Pathol 2004;21:10–17.CrossRefGoogle ScholarPubMed

Pearlman, MD, Griffin, JL. Benign breast disease. Obstet Gynecol 2010;116:747–758.Google Scholar

Tan, BY, Tan, PH. A diagnostic approach to fibroepithelial breast lesions. Surg Pathol Clin 2018;11:17–42.Google Scholar

Salemis, NS, Gemenetzis, G, Karagkiouzis, G, et al. Tubular adenoma of the breast: a rare presentation and review of the literature. J Clin Med Res 2012;4:64–67.Google ScholarPubMed

Baker, TP, Lenert, JT, Parker, JB, et al. Lactating adenoma: a diagnosis of exclusion. Breast J 2001;7:354–357.Google Scholar

Tse, GM, Law, BK, Ma, TK, et al. Hamartoma of the breast: a clinicopathological review. J Clin Pathol 2002;55:951–954.Google Scholar

Lanng, C, Eriksen, B, Hoffmann, J. Lipoma of the breast: a diagnostic dilemma. Breast 2004;13:408–411.Google Scholar

Bowman, E, Oprea, G, Okoli, J, et al. Pseudoangiomatous stromal hyperplasia (PASH) of the breast: a series of 24 patients. Breast J 2012;18:242–247.Google Scholar

Visscher, DW, Nassar, A, Degnim, AC, et al. Sclerosing adenosis and risk of breast cancer. Breast Cancer Res Treat 2014;144:205–212.Google Scholar

Berg, JC, Visscher, DW, Vierkant, RA, et al. Breast cancer risk in women with radial scars in benign breast biopsies. Breast Cancer Res Treat 2008;108:167–174.Google Scholar

Bevers, TB, Helvie M, KE, Bonaccio, EMB, et al. Breast cancer screening and diagnosis, version 3.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2018;16:1362–1389.Google Scholar

Lavoué, V, Fritel, X, Antoine, M, et al. Clinical practice guidelines from the French College of Gynecologists and Obstetricians (CNGOF): benign breast tumors – short text. Eur J Obstet Gynecol Reprod Biol 2016;200:16–23.Google Scholar

Yu, JH, Kim, MJ, Cho, H, et al. Breast diseases during pregnancy and lactation. Obstet Gynecol Sci 2013; 56:143–159.Google Scholar

Xue, AS, Wolfswinkel, EM, Weathers, WM, Chike-Obi, C, Heller, L. Breast reduction in adolescents: indication, timing, and a review of the literature. J Pediatr Adolesc Gynecol 2013;26:228–233.Google Scholar

Pullyblank, AM, Davies, JD, Basten, J, Rayter, Z. Fat necrosis of the female breast: Hadfield re-visited. Breast 2001;10:388–391.Google Scholar

Li, S, Grant, CS, Degnim, A, Donohue, J. Surgical management of recurrent subareolar breast abscesses: Mayo Clinic experience. Am J Surg 2006;192:528–529.Google Scholar

Sickles, E, D’Orsi, C, Bassett, L. ACR BI-RADS ® mammography. In: ACR BI-RADS ® Atlas, Breast Imaging Reporting and Data System. Reston, VA: American College of Radiology, 2013.Google Scholar

Committee on Practice Bulletins – Gynecology. Practice bulletin No. 164: diagnosis and management of benign breast disorders. Obstet Gynecol 2016;127:e141–e156.Google Scholar

Uzan, C, Seror, JY, Seror, J. [Management of a breast cystic syndrome: Guidelines]. J Gynecol Obstet Biol Reprod (Paris) 2015;44:970–979.Google Scholar

Bevers, TB, Ward, JH, Arun, BK, et al. Breast cancer risk reduction, version 2.2015. J Natl Compr Canc Netw 2015;13:880–915.Google Scholar